Zobrazeno 1 - 10 of 15 pro vyhledávání: '"Clare Spooner"'
2
Akademický článek
Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme
Autor: Timothy Iveson, Angela M. Carter, Kai-Keen Shiu, Clare Spooner, Daniel Stevens, Saifee Mullamitha
Publikováno v: BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)
Abstract Background The standard first- and second- line chemotherapy backbone regimens for metastatic colorectal cancer (mCRC) are 5-fluorouracil (5-FU)/capecitabine-based with addition of irinotecan or oxaliplatin. Until recently, evidence for opti
Externí odkaz: https://doaj.org/article/229d9bcaf8e94a7ca6e073aab8cd592e
Zobrazit plný text záznamu
6
Quality-Adjusted Time without Symptoms or Toxicity: Analysis of Axicabtagene Ciloleucel versus Standard of Care in Patients with Relapsed/Refractory Large B Cell Lymphoma
Autor: Marie José Kersten, Yao Qiao, Ruchit Shah, Caitlyn Solem, Julia Thornton Snider, Christina To, Paul Cheng, Clare Spooner, Miguel-Angel Perales
Publikováno v: Transplantation and Cellular Therapy. Elsevier BV
The quality-adjusted time without symptoms or toxicity (Q-TWiST) methodology provides a comprehensive framework for treatment comparison that partitions survival time into distinct health states reflecting both treatment toxicity and disease progress
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2da8a867ea48d4ce77dd5cd1b517ec85
https://doi.org/10.1016/j.jtct.2023.01.008
Zobrazit plný text záznamu
7
Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme
Autor: Kai-Keen Shiu, Clare Spooner, Saifee Mullamitha, Daniel Stevens, Angela M. Carter, Timothy Iveson
Publikováno v: BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)
BMC Cancer
Background The standard first- and second- line chemotherapy backbone regimens for metastatic colorectal cancer (mCRC) are 5-fluorouracil (5-FU)/capecitabine-based with addition of irinotecan or oxaliplatin. Until recently, evidence for optimal seque
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::692252b6550a6326ce0027527bc32045
https://doaj.org/article/229d9bcaf8e94a7ca6e073aab8cd592e
Zobrazit plný text záznamu
8
Validity of event-free survival as a surrogate endpoint in haematological malignancy: Review of the literature and health technology assessments
Autor: Sarit Assouline, Adriana Wiesinger, Clare Spooner, Jelena Jovanović, Max Schlueter
Publikováno v: Critical reviews in oncology/hematology. 175
Event-free survival (EFS) is increasingly used as a primary endpoint in trials of haematological malignancies (HMs). A key consideration is whether EFS can reliably predict survival.We conducted a review of the scientific literature and health techno
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfc8e333d59fb2797b8c5c4502a3c8d3
https://pubmed.ncbi.nlm.nih.gov/35588937
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje